Lates News

Boran Biotechnology Port Stock Exchange announcement: The self-developed Bovolu injection (dulaglutide injection) has obtained market approval from the National Medical Products Administration for blood sugar control in adult type 2 diabetes patients. Bovolu is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist, and its commercialization in mainland China is carried out in cooperation with Shang Yao Holdings by the company.